Anne Marijn Kramer, MD, PhD, discusses follow-up data from a phase 1 trial showing that CD22-directed CAR-T therapy provides durable remissions and long-term survival after 3 years for patients with large B-cell lymphomas progressing after CD19-directed CAR-T therapy.
An integrated intervention had the greatest impact in a randomized trial
Frontline nivolumab plus chemotherapy elicited clinically meaningful long-term survival benefits vs chemotherapy alone in advanced gastric/GEJ cancer.
Trastuzumab/pertuzumab/chemotherapy was associated with higher rates of toxicity and no mpRR improvement vs chemotherapy alone in HER2+ gastric cancer.
About the survey This survey aims to evaluate oncologists’ attitudes, practices, and barriers to the use of liquid biopsy in clinical care. Your participation in…
PHILADELPHIA (January 21, 2025) — Fox Chase Cancer Center is pleased to announce the hiring of Weiran Feng, PhD, as an Assistant Professor in the…
Oncology Times reports essential clinical news for oncologists, hematologists and other cancer care
The first patient with relapsed/refractory acute myeloid leukemia has received KJ-C2320, an allogeneic CAR T-cell therapy targeting CD38 and developed using the THANK-uCAR platform, in…
This randomized phase III trial aimed to determine whether treatment with cisplatin and volume-directed radiation followed by carboplatin and paclitaxel for four cycles (chemoradiotherapy [C-RT])…
Jonathan Strosberg H. Lee Moffitt Cancer Center and Research Institute Jonathan Strosberg , Tyler Zemla , Susan Geyer , Michael Knopp , Spencer Behr ,…
